Prevenar 13 filed for approval in Japan
This article was originally published in Scrip
Executive Summary
Wyeth (Pfizer) has applied for the approval of its 13-valent pneumococcal conjugate vaccine, Prevenar 13, in Japan, for use in infants from two months to five years of age.